Sarepta Therapeutics, Inc. (SRPT)

NASDAQ: SRPT · IEX Real-Time Price · USD
129.42
-0.81 (-0.62%)
Mar 28, 2024, 10:41 AM EDT - Market open
-0.62%
Market Cap 12.22B
Revenue (ttm) 1.24B
Net Income (ttm) -535.98M
Shares Out 93.86M
EPS (ttm) -5.80
PE Ratio n/a
Forward PE 63.27
Dividend n/a
Ex-Dividend Date n/a
Volume 54,915
Open 131.16
Previous Close 130.23
Day's Range 128.61 - 131.16
52-Week Range 55.25 - 159.89
Beta 0.93
Analysts Strong Buy
Price Target 161.61 (+24.87%)
Earnings Date Apr 30, 2024

About SRPT

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 3, 1997
Employees 1,314
Stock Exchange NASDAQ
Ticker Symbol SRPT
Full Company Profile

Financial Performance

In 2023, SRPT's revenue was $1.24 billion, an increase of 33.26% compared to the previous year's $933.01 million. Losses were -$535.98 million, -23.81% less than in 2022.

Financial Statements

Analyst Forecast

According to 18 analysts, the average rating for SRPT stock is "Strong Buy." The 12-month stock price forecast is $161.61, which is an increase of 24.87% from the latest price.

Price Target
$161.61
(24.87% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Sarepta Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fire...

24 days ago - Business Wire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Feb. 29, 2024 that were previously app...

27 days ago - Business Wire

Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the official opening of Route 79, The Duchenne ...

4 weeks ago - Business Wire

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and ful...

4 weeks ago - Business Wire

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2023 financial results...

5 weeks ago - Business Wire

U.S. FDA to not conduct advisers' meet for Sarepta's Duchenne gene therapy

Sarepta Therapeutics said on Friday that the U.S. FDA will not conduct a meeting of its advisers and will do a priority review for traditional approval of its gene therapy Elevidys for a muscle wastin...

5 weeks ago - Reuters

Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication

CAMBRIDGE, Mass.--(BUSINESS WIRE)--The U.S. FDA accepted and filed an efficacy supplement to expand the ELEVIDYS indication.

5 weeks ago - Business Wire

Sarepta says its experimental Duchenne drug more effective than older medicine

Sarepta Therapeutics said on Monday a mid-stage trial showed its experimental drug produced higher levels of a specific protein deficient in some patients with Duchenne muscular dystrophy (DMD), a mus...

2 months ago - Reuters

Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta announces positive data from Part B of MOMENTUM, a Phase 2 study of SRP-5051 in patients with Duchenne amenable to skipping exon 51.

2 months ago - Business Wire

Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that screening is underway in Study SRP-9003-30...

2 months ago - Business Wire

Sarepta Rebounded. Its Gene Therapy Is Back on Course.

The future of Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy looked grim two months ago. There's been a 180 since.

2 months ago - Barrons

Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and full-year 2023 n...

2 months ago - Business Wire

Dyne Therapeutics stock gains, Sarepta falls after muscular dystrophy trial results

Dyne Therapeutics Inc. shares DYN, -1.80% jumped 40% premarket on Wednesday after the company released new data from trials of two investigational treatments for genetic muscle disorders. The experime...

Other symbols: DYN
3 months ago - Market Watch

Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 42nd...

3 months ago - Business Wire

Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta submits efficacy supplement to expand ELEVIDYS label to include Duchenne patients without restriction to age or ambulatory status.

3 months ago - Business Wire

Insider Buys: Lumen, Air Products, Inari, Remitly and Sarepta

Hosted by Brian Sullivan, “Last Call” is a fast-paced, entertaining business show that explores the intersection of money, culture and policy. Tune in Monday through Friday at 7 p.m.

Other symbols: APDRELYNARILUMN
4 months ago - CNBC Television

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT

NEW YORK , Nov. 4, 2023 /PRNewswire/ -- WHY:  Rosen Law Firm, a global investor rights law firm, continues investigating potential securities claims on behalf of shareholders of Sarepta Therapeutics, ...

5 months ago - PRNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

NEW YORK , Nov. 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are advis...

5 months ago - PRNewsWire

Sarepta Therapeutics to Present at the UBS Biopharma Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fi...

5 months ago - Business Wire

Sarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate Developments

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter 2023. “T...

5 months ago - Business Wire

ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, continues investigating potential securities claims on behalf of shareholders of Sarepta Therapeutics, Inc. (NASDAQ: ...

5 months ago - Business Wire

Sarepta shares slump as muscle disorder therapy fails to meet key trial goal

Sarepta Therapeutics shares fell over 42% in premarket trading on Tuesday, after its gene therapy for a progressive muscle-wasting disorder failed to meet the main goal in a trial that was key to the ...

5 months ago - Reuters

Sarepta Therapeutics shares plunge as gene therapy trial falls short of primary goal

Sarepta Therapeutics Inc. shares SRPT, +0.77% dropped more than 40% premarket on Tuesday after the company said a trial of its gene therapy for Duchenne muscular dystrophy fell short of its main goal.

5 months ago - Market Watch

Sarepta Stock Sinks on Mixed Gene Therapy Results

In a gene therapy study for patients with Duchenne muscular dystrophy, the primary endpoint was not met.

5 months ago - Barrons

Sarepta's gene therapy fails to meet primary goal in rare muscular dystrophy trial

Sarepta Therapeutics' gene therapy to treat Duchenne muscular dystrophy failed to reach statistical significance in a late-stage trial, the company reported after the bell on Monday.

5 months ago - Reuters